Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A tripeptide (glutamate-cysteine-glycine) that is the body's most abundant endogenous antioxidant. Plays a critical role in detoxification, immune function, and cellular protection. Available in oral, IV, and injectable forms.
A synthetic tetrapeptide that targets the inner mitochondrial membrane, specifically binding to cardiolipin — a phospholipid critical for mitochondrial function. Developed by Stealth BioTherapeutics, SS-31 has been studied for heart failure, kidney disease, and age-related mitochondrial dysfunction.
Neutralizes reactive oxygen species (ROS) and free radicals. Conjugates toxins for excretion via the liver (Phase II detoxification). Regenerates other antioxidants (vitamins C and E). Supports T-cell function and immune regulation.
Concentrates in the inner mitochondrial membrane where it binds cardiolipin, stabilizing the electron transport chain and reducing reactive oxygen species (ROS) production. Improves mitochondrial efficiency without affecting membrane potential. Reduces ischemia-reperfusion injury by protecting mitochondrial structure during oxidative stress.
- Antioxidant support
- Liver detoxification
- Skin brightening
- Immune support
- Heavy metal chelation support
- Anti-aging
- Mitochondrial dysfunction support
- Cardiac protection
- Kidney protection (renal ischemia)
- Age-related energy decline
- Exercise performance and recovery
- Oral bioavailability is poor (liposomal forms better)
- IV glutathione generally well-tolerated
- Rare allergic reactions
- Skin lightening effect is controversial
- May interfere with chemotherapy drugs
- Limited human clinical data outside of specific disease trials
- Injection site reactions
- Phase 3 trial for heart failure (PROGRESS-HF) did not meet primary endpoint
- Long-term safety profile not established for general use
Available as a dietary supplement (oral) and through IV clinics. Not FDA-approved for any medical indication. No regulatory restrictions on supplement form.
Currently in clinical trials for heart failure with preserved ejection fraction (HFpEF) and other mitochondrial diseases. Phase 3 PROGRESS-HF trial results were mixed. Not FDA-approved. Available as a research chemical. Not affected by the 2026 compounding regulatory changes.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.